FSP and COVID-19: Impact on Clinical Trial Development

July 17, 2020

The functional service provider (FSP) outsourcing model enables sponsors to efficiently and cost-effectively manage workforce needs across clinical portfolios. FSP models proved to be a strategic asset during the coronavirus pandemic when the ability to increase resource flexibility and provide targeted access to specific expertise became critical to clinical trial continuity.  

Previous Article
Case Study: Parexel® Medical Imaging Supports AbbVie’s Elagolix

Recently, Parexel supported a Phase III study of AbbVie’s Elagolix, a uterine fibroid treatment, that incor...

Next Article
What’s Around the Corner for FDA Inspections?
What’s Around the Corner for FDA Inspections?

There have been two recent activities from the U.S. Food and Drug Administration (FDA) that provide industr...